Table 3.
Comparison of clinicopathological features of HCC patients according to the serum HBsAg level
| HBsAg level (S/CO) | p value | ||
|---|---|---|---|
|
|
|||
| < 2000 (n = 137) | ≥ 2000 (n = 689) | ||
| Age (mean ± SD, years) | 54.6 ± 10.4 | 50.4 ± 10.6 | < 0.001 |
| Cirrhosis (%) | 72 (52.6) | 462 (67.1) | 0.001 |
| Anti-HBV therapy (%) (n = 691)a | < 0.001 | ||
| No | 61 (52.1) | 147 (25.6) | |
| Yes | 56 (47.9) | 427 (74.4) | |
| Seropositive HBeAg (%) | 25 (18.2) | 207 (30.0) | 0.005 |
| Serum HBV DNA level (IU/mL) (%) (n = 773)a | < 0.001 | ||
| ≥ 2000 | 36 (28.8) | 392 (60.5) | |
| < 2000 | 89 (71.2) | 256 (39.5) | |
| ALT (U/L) | 0.010 | ||
| > 41 | 43 (31.4) | 298 (43.3) | |
| ≤ 41 | 94 (68.6) | 391 (56.7) | |
| AST (U/L) | 0.020 | ||
| > 37 | 43 (31.4) | 290 (42.1) | |
| ≤ 37 | 94 (68.6) | 399 (57.9) | |
| Prealbumin (mg/L) | 0.054 | ||
| < 170 | 26 (19.0) | 185 (26.9) | |
| ≥ 170 | 111 (81.0) | 504 (73.1) | |
HCC: hepatocellular carcinoma; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen; ALT: alanine transaminase; AST: aspartate aminotransferase.
a
Number of available data.